Skip to main content
Erschienen in: Journal of Neurology 5/2011

01.05.2011 | Original Communication

Comparison of muscle ultrastructure in myasthenia gravis with anti-MuSK and anti-AChR antibodies

verfasst von: Giovanna Cenacchi, Papa Valentina, Fanin Marina, Pegoraro Elena, Angelini Corrado

Erschienen in: Journal of Neurology | Ausgabe 5/2011

Einloggen, um Zugang zu erhalten

Abstract

Patients with myasthenia gravis (MG) with antibodies to muscle-specific receptor tyrosine kinase (MuSK) differ from acetylcholine receptor (AChR)-positive MG patients, as they frequently present with severe oculobulbar muscle weakness or with neck, shoulder, and respiratory muscle involvement. The neuromuscular junction (NMJ) has been confirmed to be the main target of both AChR- and MuSK-MG. However, histopathological investigation disclosed that muscle fiber atrophy was prevalent in AChR-MG, whereas mild myopathic changes and mitochondrial abnormalities were more frequently observed in MuSK-MG. As the pathogenetic mechanism in MuSK-MG remains unclear, this study investigated the submicroscopic pattern of muscle histopathology to establish a possible correlation between clinical involvement and subcellular morphological findings. Muscle biopsies from seven MuSK-MG patients and from seven patients with AChR-MG were analyzed by transmission electron microscopy. Myopathic and mitochondrial abnormalities were more prominent in MuSK-MG and show giant, swollen, and degenerated mitochondria with fragmented cristae. The most common changes in AChR-MG muscles were fiber atrophy, myofibrillar disarray, and Z-line streaming, consistent with mild neurogenic abnormalities. A different pathogenetic mechanism is emerging in MuSK-MG compared to AChR-MG. Mitochondrial abnormalities seem to be more prominent in MuSK-MG, whereas neurogenic atrophy is observed in AChR-MG.
Literatur
2.
Zurück zum Zitat Keesey JC (2004) Clinical evaluation and management of myasthenia gravis. Muscle Nerve 29:484–505PubMedCrossRef Keesey JC (2004) Clinical evaluation and management of myasthenia gravis. Muscle Nerve 29:484–505PubMedCrossRef
3.
Zurück zum Zitat Angelini C (1994) Miastenia grave: progressi clinici. Piccin Editor, pp 209–220 Angelini C (1994) Miastenia grave: progressi clinici. Piccin Editor, pp 209–220
4.
Zurück zum Zitat Jaretski III, Bahron RJ, Ernstoff RM et al (2000) Myasthenia gravis: recommendations for clinical research standards. Neurology 55:16–23 Jaretski III, Bahron RJ, Ernstoff RM et al (2000) Myasthenia gravis: recommendations for clinical research standards. Neurology 55:16–23
5.
Zurück zum Zitat Mossman S, Vincent A, Newsom-Davis J (1986) Myasthenia gravis without acetylcholine receptor antibody: a distinct disease entity. Lancet 1:116–119PubMedCrossRef Mossman S, Vincent A, Newsom-Davis J (1986) Myasthenia gravis without acetylcholine receptor antibody: a distinct disease entity. Lancet 1:116–119PubMedCrossRef
6.
Zurück zum Zitat Hoch W, McConville J, Helms J et al (2001) Auto-antibodies to the receptor tyrosin-kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 7:365–368PubMedCrossRef Hoch W, McConville J, Helms J et al (2001) Auto-antibodies to the receptor tyrosin-kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 7:365–368PubMedCrossRef
7.
Zurück zum Zitat Nemoto Y, Kuwabara S, Misawa N et al (2005) Patterns and severity of neuromuscular transmission failure in seronegative myasthenia gravis. J Neurol Neurosurg Psychiatry 76:714–718PubMedCrossRef Nemoto Y, Kuwabara S, Misawa N et al (2005) Patterns and severity of neuromuscular transmission failure in seronegative myasthenia gravis. J Neurol Neurosurg Psychiatry 76:714–718PubMedCrossRef
8.
Zurück zum Zitat Rostedt Punga A, Ahlqvist K, Bartoccioni E et al (2006) Neurophysiological and mitochondrial abnormalities in MuSK antibody seropositive myasthenia gravis compared to other immunological subtypes. Clin Neurophysiol 117:1434–1443PubMedCrossRef Rostedt Punga A, Ahlqvist K, Bartoccioni E et al (2006) Neurophysiological and mitochondrial abnormalities in MuSK antibody seropositive myasthenia gravis compared to other immunological subtypes. Clin Neurophysiol 117:1434–1443PubMedCrossRef
9.
Zurück zum Zitat DeChiara TM, Bowen DC, Valenzuela DM et al (1996) The receptor tyrosin kinase MuSK is required for neuromuscular junction formation in vivo. Cell 85:501–512PubMedCrossRef DeChiara TM, Bowen DC, Valenzuela DM et al (1996) The receptor tyrosin kinase MuSK is required for neuromuscular junction formation in vivo. Cell 85:501–512PubMedCrossRef
10.
Zurück zum Zitat Deymeer F, Gungor-Tuncer O, Yilmaz V et al (2007) Clinical comparison of anti-MuSK vs anti-AChR-positive and seronegative myasthenia gravis. Neurology 68:609–611PubMedCrossRef Deymeer F, Gungor-Tuncer O, Yilmaz V et al (2007) Clinical comparison of anti-MuSK vs anti-AChR-positive and seronegative myasthenia gravis. Neurology 68:609–611PubMedCrossRef
11.
Zurück zum Zitat Romi F, Aarli, Gilhus NE (2005) Seronegative myasthenia gravis: disease severity and prognosis. Eur J Neurol 12:413–418PubMedCrossRef Romi F, Aarli, Gilhus NE (2005) Seronegative myasthenia gravis: disease severity and prognosis. Eur J Neurol 12:413–418PubMedCrossRef
12.
Zurück zum Zitat Guptill JT, Sanders DB (2010) Update on muscle-specific tyrosine kinase antibody positive myasthenia gravis. Curr Opin Neurol 23:530–535PubMedCrossRef Guptill JT, Sanders DB (2010) Update on muscle-specific tyrosine kinase antibody positive myasthenia gravis. Curr Opin Neurol 23:530–535PubMedCrossRef
13.
Zurück zum Zitat Sanders DB, El-Salem K, Massey JM et al (2003) Clinical aspects of MuSK antibody positive seronegative MG. Neurology 60:1978–1980PubMed Sanders DB, El-Salem K, Massey JM et al (2003) Clinical aspects of MuSK antibody positive seronegative MG. Neurology 60:1978–1980PubMed
14.
Zurück zum Zitat Martignago S, Fanin M, Albertini E et al (2009) Muscle histopathology in myasthenia gravis with antibodies against MuSK and AChR. Neuropathol Appl Neurobiol 35:103–110PubMedCrossRef Martignago S, Fanin M, Albertini E et al (2009) Muscle histopathology in myasthenia gravis with antibodies against MuSK and AChR. Neuropathol Appl Neurobiol 35:103–110PubMedCrossRef
15.
Zurück zum Zitat Farrugia ME, Robson MD, Clover L et al (2006) MRI and clinical studies of facial and bulbar muscle involvement in MuSK antibody-associated myasthenia gravis. Brain 129:1481–1492PubMedCrossRef Farrugia ME, Robson MD, Clover L et al (2006) MRI and clinical studies of facial and bulbar muscle involvement in MuSK antibody-associated myasthenia gravis. Brain 129:1481–1492PubMedCrossRef
16.
Zurück zum Zitat Selcen D, Fukuda T, Shen XM et al (2004) Are MuSK antibodies the primary cause of myasthenic symptoms? Neurology 62:1945–1950PubMed Selcen D, Fukuda T, Shen XM et al (2004) Are MuSK antibodies the primary cause of myasthenic symptoms? Neurology 62:1945–1950PubMed
17.
Zurück zum Zitat Niks EH, Kuks JBM, Wokke JHJ et al (2010) Pre-postsynaptic neuromuscular junction abnormalities in MuSK. Myasthenia Muscle Nerve 42:283–288CrossRef Niks EH, Kuks JBM, Wokke JHJ et al (2010) Pre-postsynaptic neuromuscular junction abnormalities in MuSK. Myasthenia Muscle Nerve 42:283–288CrossRef
18.
Zurück zum Zitat Vincent A (2008) Autoimmune disorders of the neuromuscular junction. Neurol India 56:305–313PubMedCrossRef Vincent A (2008) Autoimmune disorders of the neuromuscular junction. Neurol India 56:305–313PubMedCrossRef
19.
Zurück zum Zitat Shiraishi H, Motomura M, Yoshimura T et al (2005) Acetylcholine receptors loss and postsynaptic damage in MuSK antibody-positive myasthenia gravis. Ann Neurol 57:289–293PubMedCrossRef Shiraishi H, Motomura M, Yoshimura T et al (2005) Acetylcholine receptors loss and postsynaptic damage in MuSK antibody-positive myasthenia gravis. Ann Neurol 57:289–293PubMedCrossRef
20.
Zurück zum Zitat Wang Q, Zhang B, Xiong WC et al (2006) MuSK signalling at the neuromuscular junction. J Mol Neurosci 30:223–226PubMedCrossRef Wang Q, Zhang B, Xiong WC et al (2006) MuSK signalling at the neuromuscular junction. J Mol Neurosci 30:223–226PubMedCrossRef
21.
Zurück zum Zitat Benveniste O, Jacobson L, Farrugia ME et al (2005) MuSK antibody positive myasthenia gravis plasma modifies MURF-1 expression in C2C12 cultures and mouse muscles in vivo. J Neuroimmunol 170:41–48PubMedCrossRef Benveniste O, Jacobson L, Farrugia ME et al (2005) MuSK antibody positive myasthenia gravis plasma modifies MURF-1 expression in C2C12 cultures and mouse muscles in vivo. J Neuroimmunol 170:41–48PubMedCrossRef
22.
Zurück zum Zitat Farrugia ME, Bonifati DM, Clover L et al (2007) Effect of sera from AChR-antibody negative myasthenia gravis patients on AChR and MuSK in cell cultures. J Neuroimmunol 185:136–144PubMedCrossRef Farrugia ME, Bonifati DM, Clover L et al (2007) Effect of sera from AChR-antibody negative myasthenia gravis patients on AChR and MuSK in cell cultures. J Neuroimmunol 185:136–144PubMedCrossRef
23.
Zurück zum Zitat Caress JB, Hunt CH, Batish SD (2005) Anti-MuSK myasthenia gravis presenting with purely ocular findings. Arch Neurol 62:1002–1003PubMedCrossRef Caress JB, Hunt CH, Batish SD (2005) Anti-MuSK myasthenia gravis presenting with purely ocular findings. Arch Neurol 62:1002–1003PubMedCrossRef
24.
Zurück zum Zitat Hain B, Hanisch F, Deschauer M (2004) Seronegative myasthenia with antibodies against muscle-specific tyrosin kinase. Nervenartz 75:362–367CrossRef Hain B, Hanisch F, Deschauer M (2004) Seronegative myasthenia with antibodies against muscle-specific tyrosin kinase. Nervenartz 75:362–367CrossRef
25.
Zurück zum Zitat Lavrnic D, Losen M, Vujic A et al (2005) The features of myasthenia gravis with autoantibodies to MuSK. J Neurol Neurosurg Psychiat 76:1099–1102PubMedCrossRef Lavrnic D, Losen M, Vujic A et al (2005) The features of myasthenia gravis with autoantibodies to MuSK. J Neurol Neurosurg Psychiat 76:1099–1102PubMedCrossRef
26.
Zurück zum Zitat Stickler DE, Massey JM, Sanders DB (2005) MuSK- antibody positive myasthenia gravis: clinical and electrodiagnostic patterns. Clin Neurophysiol 116:2065–2068PubMedCrossRef Stickler DE, Massey JM, Sanders DB (2005) MuSK- antibody positive myasthenia gravis: clinical and electrodiagnostic patterns. Clin Neurophysiol 116:2065–2068PubMedCrossRef
27.
Zurück zum Zitat Soltys J, Gong B, Kaminski HJ et al (2008) Extraocular muscle susceptibility to myasthenia gravis. Unique immunological environment? Ann N Y Acad Sci 1132:220–224PubMedCrossRef Soltys J, Gong B, Kaminski HJ et al (2008) Extraocular muscle susceptibility to myasthenia gravis. Unique immunological environment? Ann N Y Acad Sci 1132:220–224PubMedCrossRef
28.
Zurück zum Zitat Yu Wai Man CY, Chinnery PF, Griffiths PG (2005) Extraocular muscles have fundamentally distinct properties that make them selectively vulnerable to certain disorders. Neuromuscul Disord 15:17–23PubMedCrossRef Yu Wai Man CY, Chinnery PF, Griffiths PG (2005) Extraocular muscles have fundamentally distinct properties that make them selectively vulnerable to certain disorders. Neuromuscul Disord 15:17–23PubMedCrossRef
29.
Zurück zum Zitat Dupuis L, Gonzales de Aguilar JL, Echaniz-Laguna A et al (2009) Muscle mitochondrial uncoupling dismantles neuromuscular junction and triggers distal degeneration of motor neurons. Plos One 4:e5390PubMedCrossRef Dupuis L, Gonzales de Aguilar JL, Echaniz-Laguna A et al (2009) Muscle mitochondrial uncoupling dismantles neuromuscular junction and triggers distal degeneration of motor neurons. Plos One 4:e5390PubMedCrossRef
30.
Zurück zum Zitat Xu K, Jha S, Hoch W, Dryer SE (2006) Delayed synapsing muscles are more severely affected in an experimental model of MuSK-induced myasthenia gravis. Neuroscience 143:655–659PubMedCrossRef Xu K, Jha S, Hoch W, Dryer SE (2006) Delayed synapsing muscles are more severely affected in an experimental model of MuSK-induced myasthenia gravis. Neuroscience 143:655–659PubMedCrossRef
31.
Zurück zum Zitat MacAskill AF, Rinholm JE, Twelvetrees AE et al (2009) Miro1 is a calcium sensor for glutamate receptor-dependent localization of mitochondrial at synapses. Neuron 61:541–555PubMedCrossRef MacAskill AF, Rinholm JE, Twelvetrees AE et al (2009) Miro1 is a calcium sensor for glutamate receptor-dependent localization of mitochondrial at synapses. Neuron 61:541–555PubMedCrossRef
32.
Zurück zum Zitat Pesce V, Cormio A, Fracasso F et al (2001) Age-related mitochondrial genotypic and phenotypic alterations in human skeletal muscles. Free Rad Biol Med 30:1223–1233PubMedCrossRef Pesce V, Cormio A, Fracasso F et al (2001) Age-related mitochondrial genotypic and phenotypic alterations in human skeletal muscles. Free Rad Biol Med 30:1223–1233PubMedCrossRef
33.
Zurück zum Zitat Dobbins GC, Luo S, Yang Z et al (2008) Alpha-actinin interacts with rapsyn in agrin-stimulated AChR clustering. Mol Brain 1(1):18PubMedCrossRef Dobbins GC, Luo S, Yang Z et al (2008) Alpha-actinin interacts with rapsyn in agrin-stimulated AChR clustering. Mol Brain 1(1):18PubMedCrossRef
34.
Zurück zum Zitat Spillane J, Beeson DJ, Kullmann DM (2010) Myasthenia and related disorders of the neuromuscular junction. J Neurol Neurosurg Psychiatry 81:850–857PubMedCrossRef Spillane J, Beeson DJ, Kullmann DM (2010) Myasthenia and related disorders of the neuromuscular junction. J Neurol Neurosurg Psychiatry 81:850–857PubMedCrossRef
35.
Zurück zum Zitat Vincent A, Leite MI (2005) Neuromuscular junction autoimmune disease: muscle specific kinase antibodies and treatments for myasthenia gravis. Curr Opin Neurol 18:519–525PubMedCrossRef Vincent A, Leite MI (2005) Neuromuscular junction autoimmune disease: muscle specific kinase antibodies and treatments for myasthenia gravis. Curr Opin Neurol 18:519–525PubMedCrossRef
36.
Zurück zum Zitat Vincent A, Bowen J, Newsom-Davis J et al (2003) Seronegative generalised myasthenia gravis: clinical features, antibodies, and their target. Lancet Neurol 2:99–106PubMedCrossRef Vincent A, Bowen J, Newsom-Davis J et al (2003) Seronegative generalised myasthenia gravis: clinical features, antibodies, and their target. Lancet Neurol 2:99–106PubMedCrossRef
Metadaten
Titel
Comparison of muscle ultrastructure in myasthenia gravis with anti-MuSK and anti-AChR antibodies
verfasst von
Giovanna Cenacchi
Papa Valentina
Fanin Marina
Pegoraro Elena
Angelini Corrado
Publikationsdatum
01.05.2011
Verlag
Springer-Verlag
Erschienen in
Journal of Neurology / Ausgabe 5/2011
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-010-5823-x

Weitere Artikel der Ausgabe 5/2011

Journal of Neurology 5/2011 Zur Ausgabe

Letter to the Editors

A urinary cause of coma

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.